Altimmune Pemvidutide significant weight loss and decreases in pro-inflammatory serum lipids

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), on cardioinflammatory lipids at the American Diabetes Association’s (ADA) 84th Scientific Sessions.

“Dyslipidemia is one of the most significant co-morbidities of obesity, impacting up to 70% of patients with obesity,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “These data add to the differentiated profile of pemvidutide and reinforce its potential to reduce inflammatory lipids associated with cardiovascular plaque formation and cardiovascular risk in patients with obesity.”

https://www.globenewswire.com/news-release/2024/06/22/2902664/0/en/Altimmune-Presents-Data-on-the-Effect-of-Pemvidutide-on-Cardioinflammatory-Lipids-during-Oral-Presentation-at-American-Diabetes-Association-s-84th-Annual-Scientific-Sessions.html